NCT05422378View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

February 3, 2023

Study Completion Date

June 27, 2023

Conditions
Abdominal Obesity
Interventions
DRUG

STP705

STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.

Trial Locations (1)

33180

Center for Clinical and Cosmetic Research, Aventura

Sponsors

Lead Sponsor

Sirnaomics
All Listed Sponsors
lead

Sirnaomics

INDUSTRY

NCT05422378 - A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty | Biotech Hunter | Biotech Hunter